Trial
NCT03702829
24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Brigham and Women's Hospital
Collaborators
—
Condition
Amyloidosis
Intervention
Inotersen
Why stopped
recruitment of new patients not possible during Covid 19 epidemic
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-20